Is Chlorprothixene registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Chlorprothixene, including TRUXAL TABLETS 50MG (50 mg, Film-coated tablet, SAR 26.55).

Is Chlorprothixene approved by the US FDA?

Drugs@FDA lists 3 application product lines for Chlorprothixene, including TARACTAN (Discontinued); TARACTAN (Discontinued); TARACTAN (Discontinued).

Active substance

Chlorprothixene

SFDA 1
US FDA 3

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
TRUXAL TABLETS 50MG	50 mg	Film-coated tablet · Oral use	50 Tablet Container	SAR 26.55	NCE · Prescription	H. LUNDBECK	Valid

Indications — CHI Daman Drug Formulary

SCHIZOPHRENIA

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
TARACTAN	12.5MG/ML	injectable · injection	ROCHE	Discontinued	23 Mar 1962
TARACTAN	100MG; 50MG; 25MG; 10MG	tablet · oral	ROCHE	Discontinued	7 May 1962
TARACTAN	100MG/5ML	concentrate · oral	ROCHE	Discontinued	19 Jun 1967

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.